Latham Advises TPG and DOC Pharma on €990 Million High Yield Bond and €150 Million RCF

Latham & Watkins has advised TPG and its portfolio company DOC Pharma, a leading Italian generic pharmaceutical company, on a €990 million senior secured notes offering, composed of €400 million aggregate principal amount of senior secured floating rate notes due 2032 and €590 million aggregate principal amount of 5.625% senior secured notes due 2032, and on a €150 million multi-currency revolving credit facility to refinance existing indebtedness. The transactions are expected to close subject to customary closing conditions.

The Latham team was led by capital markets partner Francesco Lione, with assistance from Peter Neuböck, and with associate Sonali Ladha. Advice on banking matters was provided by London partner Charles Armstrong, with associates Alexander Law and Vanessa Ho; on Italian finance matters by Milan partner Alessia De Coppi and counsel Erika Brini Raimondi, with associates Simona Di Marcantonio, Maria Cristina Grechi, and trainee Benedetta Doria; on Italian regulatory matters by Milan partner Cesare Milani, with associates Edoardo Cassinelli and Irene Terenghi; on Italian capital markets matters by associate Marco Bonasso and trainee Alberto Tognon; and on tax matters by New York partner Jocelyn Noll and Madrid counsel Blanca Vazquez de Castro, with associate Chris Zhao.